Tapering of Rituximab Based on Interval Prolongation Compared to Disease Activity-guided Dose Reduction in Patients With Rheumatoid Arthritis
Condition: Rheumatoid Arthritis Intervention: Drug: Rituximab Sponsors: Universitaire Ziekenhuizen KU Leuven; Fonds voor Wetenschappelijk Reumaonderzoek (FWRO) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials